XOMA (NASDAQ:XOMA) Posts Quarterly Earnings Results, Misses Expectations By $0.17 EPS

XOMA (NASDAQ:XOMA) issued its earnings results on Monday. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17), Zacks reports. The firm had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%.

XOMA Stock Up 0.8 %

XOMA stock opened at $20.89 on Wednesday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a twelve month low of $19.92 and a twelve month high of $35.00. The company’s 50 day moving average is $24.64 and its two-hundred day moving average is $27.29. The stock has a market cap of $246.15 million, a P/E ratio of -6.00 and a beta of 1.00.

Analyst Ratings Changes

XOMA has been the topic of several analyst reports. StockNews.com cut shares of XOMA from a “hold” rating to a “sell” rating in a report on Tuesday, February 25th. HC Wainwright cut their price objective on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a report on Monday, February 3rd.

Insider Transactions at XOMA

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 7.20% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.